Shares of CymaBay Therapeutics Inc. CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage study of seladelpar, its investigational treatment for the rare chronic liver disease primary biliary cholangitis. About 62% of patients treated with seladelpar met the study’s primary endpoint related to serum alkaline phosphatase and bilirubin, compared with 20% of those on placebo, CymaBay said in a release. The study also met key secondary endpoints, including a significant reduction of pruritis, or itching that is a common early symptom of the disease, CymaBay said. The trial data support filing for approval of the treatment with U.S. and European regulators, the company said. CymaBay shares have gained 120% in the year to date, while the S&P 500 SPX has gained 16.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.